[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Fouladi M, Blaney SM, Poussaint TY, Freeman BB 3rd, McLendon R, Fuller C, Adesina AM, Hancock ML, Danks MK, Stewart C, Boyett JM, Gajjar A: Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer; 2006 Nov 1;107(9):2291-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
  • BACKGROUND: An open-label Phase II study of oxaliplatin was conducted to evaluate its safety and efficacy in children with recurrent or refractory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET), and atypical teratoid rhabdoid tumor (ATRT).
  • The primary objective was to estimate the sustained response rate in stratum 1A.
  • [MeSH-major] Medulloblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Organoplatinum Compounds / therapeutic use. Rhabdoid Tumor / drug therapy. Supratentorial Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Male. Treatment Outcome


2. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW: Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol; 2009 Jan 20;27(3):385-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor.
  • PURPOSE: Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, with a historic median survival ranging from 6 to 11 months.
  • PATIENTS AND METHODS: Treatment was divided into five phases: preirradiation, chemoradiation, consolidation, maintenance, and continuation therapy.
  • Intrathecal chemotherapy was administered, alternating intralumbar and intraventricular routes.
  • Radiation therapy (RT) was prescribed, either focal (54 Gy) or craniospinal (36 Gy, plus primary boost), depending on age and extent of disease at diagnosis.
  • Gross total resection of the primary tumor was achieved in 11 patients.
  • Fifteen patients received radiation therapy: 11 focal and four craniospinal.
  • CONCLUSION: This intensive multimodality regimen has resulted in a significant improvement in time to progression and overall survival for patients with this previously poor-prognosis tumor.
  • [MeSH-major] Brain Neoplasms / therapy. Rhabdoid Tumor / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Infratentorial Neoplasms. Prognosis. Prospective Studies. Supratentorial Neoplasms. Young Adult

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):235-40 [18381756.001]
  • [Cites] Radiology. 1969 Dec;93(6):1351-9 [4983156.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):332-7 [3030922.001]
  • [Cites] Pediatr Neurol. 1991 Jul-Aug;7(4):237-42 [1930413.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):258 [1637409.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):71-5 [7743242.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1013-9 [9719110.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):77-84 [15803379.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):478-86 [15918215.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E8 [16048294.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] J Pediatr Psychol. 2007 Sep;32(8):918-25 [17522113.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • (PMID = 19064966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / R01 CA046274-17A2; United States / NCI NIH HHS / CA / CA46274
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2645855
  •  go-up   go-down


3. Beppu T, Yoshida Y, Arai H, Wada T, Suzuki M, Ogawa A, Hakozaki S, Kubo N: A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas. J Neurooncol; 2000 Sep;49(3):213-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.
  • Twenty-eight patients who were previously treated by aggressive surgery and radiation and were diagnosed with supratentorial malignant gliomas received a combination of nimustine hydrochloride; 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cisplatin and etoposide (ACE therapy) as primary treatment.
  • Treatment was repeated at 4-week intervals for up to 3 cycles.
  • The median time of tumor progression was 40 weeks, and the median survival time was 146 weeks.
  • This study demonstrated the effects of ACE combination in patients with supratentorial malignant gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Glioma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Nimustine / administration & dosage. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):55-9 [7942182.001]
  • [Cites] J Clin Oncol. 1984 May;2(5):432-7 [6726296.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2229-35 [9038603.001]
  • [Cites] Neurosurgery. 1987 Aug;21(2):201-6 [2821446.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 May;33(5):295-9 [7687035.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 May;44(5):397-401 [7021770.001]
  • [Cites] Cancer Treat Rev. 1985 Sep;12 Suppl A:125-36 [3002623.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2474-9 [6280860.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1986 Jan;64(1):53-7 [3455717.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):794-9 [6331626.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):1-9 [2661738.001]
  • [Cites] Cancer Treat Rep. 1976 Nov;60(11):1619-25 [1021234.001]
  • [Cites] J Neurooncol. 1991 Oct;11(2):165-70 [1744684.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Aug;36(8):555-8; discussion 558-9 [8831197.001]
  • [Cites] J Neurooncol. 1994;19(3):227-37 [7807173.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):155-60 [9120545.001]
  • (PMID = 11212900.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0S726V972K / Nimustine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Timmermann B, Kortmann RD, Kühl J, Meisner C, Dieckmann K, Pietsch T, Bamberg M: Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol; 2002 Feb 01;20(3):842-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91.
  • PURPOSE: To evaluate the outcome of children with supratentorial primitive neuroectodermal tumors after surgery, irradiation, and chemotherapy and to identify factors predictive for survival.
  • Patients were randomized for preirradiation chemotherapy, consisting of two cycles of ifosfamide, etoposide, methotrexate, cisplatin, and cytarabine (n = 40), or chemotherapy after irradiation, consisting of eight cycles with cisplatin, vincristine, and lomustine (n = 23).
  • Irradiation volume was recommended to encompass the neuraxis with 35.2-Gy total dose followed by a boost (20.0 Gy) to the primary tumor site (n = 54).
  • Seven patients were irradiated to the tumor region only with a total dose of 54.0 Gy.
  • The only significant prognostic factor was dose and volume of radiotherapy (progression-free survival after 3 years was 49.3% with correct treatment compared with 6.7% for 15 children with major violations of radiotherapy).
  • Ten early progressions occurred during adjuvant therapy (eight before and two during radiotherapy), nine of them treated with preirradiation chemotherapy.
  • Local doses of at least 54 Gy and a craniospinal dose of 35 Gy are necessary.
  • Preirradiation chemotherapy seems to increase risk of early progression.
  • [MeSH-major] Neuroectodermal Tumors / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Lomustine / administration & dosage. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local. Radiotherapy Dosage. Survival Rate. Treatment Outcome. Vincristine / administration & dosage


5. Taylor RE, Donachie PH, Weston CL, Robinson KJ, Lucraft H, Saran F, Ellison DW, Ironside J, Walker DA, Pizer BL, Children's Cancer and Leukaemia Group CNS Tumour Division: Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Radiother Oncol; 2009 Jul;92(1):83-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of radiotherapy parameters on outcome for patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study.
  • BACKGROUND AND PURPOSE: To evaluate the impact of radiotherapy (RT) parameters on outcome in the SIOP/UKCCSG study of pre-RT chemotherapy for Supratentorial Primitive Neuro-ectodermal Tumours.
  • Fifty-one were not randomized, 15 receiving RT alone and 36 receiving pre-RT chemotherapy.
  • Craniospinal RT (CSRT) 35 Gy/21 fractions were followed by 20 Gy/12 fractions to primary tumour.
  • RESULTS: Mean CSRT dose was 34.7 Gy and mean total primary dose was 53.4 Gy for those who received radiotherapy.
  • There was no significant impact on Overall Survival (OS) or Event-Free Survival (EFS) of surgery-RT interval for patients treated by pre-RT chemotherapy or RT alone, or duration of RT (completing within 50 days).
  • However, multi-institutional SPNET trials should incorporate quality assurance programs including analysis of relapse pattern in relation to primary target volume coverage.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Neuroectodermal Tumors, Primitive / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Radiation Dosage. Randomized Controlled Trials as Topic. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328574.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


6. Guinto G, Félix I, Aréchiga N, Arteaga V, Kovacs K: Primary central nervous system lymphomas in immunocompetent patients. Histol Histopathol; 2004 07;19(3):963-72
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas in immunocompetent patients.
  • Primary Central nervous system lymphoma is a rare non-Hodgkin's tumor of the brain that has been traditionally found in patients with immunodeficiency syndromes.
  • However, there are several immunocompetent patients that have also been reported with this neoplasm.
  • Macroscopically, most of the tumors are unique and mainly located in the supratentorial region in the proximity of the cerebrospinal fluid circulation.
  • The treatment is based on a combination of chemotherapy followed by radiotherapy, but the mortality rate is still high.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Methotrexate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15168358.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 63
  •  go-up   go-down


7. Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M: Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol; 2008 Jun;31(3):300-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this review is to assess the palliative effect of re-irradiation in adult patients with recurrent supratentorial glioblastoma (GBM) previously treated with adjuvant or primary radiation therapy, with or without chemotherapy.
  • Data from more than 300 GBM patients (grade 3 anaplastic gliomas were excluded) demonstrate that re-irradiation yields 6-month PFS of 28% to 39% and 1-year overall survival of 18% to 48%, without additional chemotherapy (median value 26%).
  • Patients with Karnofsky performance status <70 appeared to be at higher risk of early progression and apparently had lesser benefit from re-irradiation.
  • In the studies reporting on corticosteroid usage during and after re-irradiation, 20% to 60% of the patients achieved a reduction in steroid dependency.
  • Serious late toxicity was uncommon, especially after conventional treatment and fractionated stereotactic radiotherapy (FSRT).
  • In light of recent technological advances such as FSRT and intensity modulated radiotherapy, which permit maximal sparing of normal brain, re-treatment seems attractive, and deserves scientific validation.
  • Even fraction sizes of 3 to 5 Gy seem to be well tolerated in limited-volume recurrences as long as the total dose is limited to 30 to 35 Gy.
  • Salvage chemotherapy or targeted agents should be prospectively tested against re-irradiation alone.
  • [MeSH-major] Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Palliative Care. Quality of Life. Supratentorial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525311.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


8. Jaing TH, Wang HS, Tsay PK, Tseng CK, Jung SM, Lin KL, Lui TN: Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. J Neurooncol; 2004 Jul;68(3):255-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our retrospective series included 15 with supratentorial and 28 with infratentorial tumors.
  • Radiotherapy was done in 31 patients and chemotherapy in 13.
  • The median survival time was 30 months, and 5-year overall survival and progression-free survival rates were 53.9% and 45.9%, respectively.
  • By tumor site: supratentorial, 56.6% and 50.9%; infratentorial, 52.3% and 42.5%.
  • Only one of 15 patients with supratentorial tumors developed isolated spinal metastasis.
  • Failure at the primary site is the major obstacle to improve cure rates.
  • [MeSH-major] Ependymoma / diagnosis. Infratentorial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Supratentorial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2000;39(1):97-100 [10752661.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):117-22 [11943886.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):215-22 [9732252.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):52-7 [12007941.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23 (2):313-9 [1587752.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):295-308 [12078861.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):605-13 [11014538.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):51-7 [9874186.001]
  • [Cites] J Neurooncol. 1999;45(1):61-7 [10728911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):83-91 [2105621.001]
  • [Cites] Pediatr Neurosurg. 2001 Feb;34(2):77-87 [11287807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Pediatr Neurol. 1996 Apr;14(3):216-19 [8736405.001]
  • [Cites] Childs Nerv Syst. 2001 Feb;17(3):121-33 [11305764.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):193-9 [12691623.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):629-42, 644; discussion 645-6, 648 [12108890.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):381-6 [8276653.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1500-7 [7969301.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):11-8 [9990108.001]
  • [Cites] Childs Nerv Syst. 2000 Mar;16(3):170-5 [10804053.001]
  • [Cites] Paediatr Drugs. 2003;5(8):533-43 [12895136.001]
  • (PMID = 15332330.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. El-Gaidi MA, Eissa EM: Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center. Pediatr Neurosurg; 2010;46(4):272-82
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center.
  • OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common neoplasm in infants.
  • RESULTS: Out of 451 patients with primary intracranial neoplasms (age 0-14 years), 21 infants (<1 year) underwent surgery, representing 4.7% of total cases.
  • Of the 21 surgical cases, 90% were intra-axial, 80% were in the supratentorial region, and 57% were intraventricular.
  • Three patients received chemotherapy, but none received radiotherapy.
  • CONCLUSION: Although the prognosis for infantile intracranial neoplasms is worse than for older children, an overall promising outcome with low operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant chemotherapy as part of a multidisciplinary approach.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Papilloma, Choroid Plexus / mortality. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21160236.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Sipos L, Vitanovics D, Afra D: [Treatment of recidive malignant gliomas with temozolomide]. Orv Hetil; 2002 May 26;143(21):1201-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of recidive malignant gliomas with temozolomide].
  • In case of recurrencies reoperation is rarely possible and chemotherapy is the last treatment modality.
  • The treatment had to be stopped in four cases.
  • The mean progress free interval was 6.25 and the mean survival time 9 months.
  • According to the primary histology the mean survival time for glioblastoma patients was 6.8 and for anaplastic astrocytoma or mixed oligoastrocytoma patients 12.2 months.
  • CONCLUSIONS: Due to its low toxicity and relatively long survival time after recurrency temozolomide seems to be a promising drug in the treatment of recurrent malignant gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12073541.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


11. Sands S, Van Gorp WG, Finlay JL: A dramatic loss of non-verbal intelligence following a right parietal ependymoma: brief case report. Psychooncology; 2000 May-Jun;9(3):259-66
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report presents the case of a 19-year-old left-handed male with assessment of Verbal and Performance I.Q. testing 1 year prior to a subsequent brain tumor for reasons unrelated to the neoplasm.
  • The patient was then re-tested 23 months later, following the diagnosis and treatment of a supratentorial ependymoma in the right parietal region.
  • His multi-modal treatment regimen included a partial surgical resection of the tumor, cranio-spinal irradiation with focal boost to the primary site, and chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Cognition Disorders / etiology. Ependymoma / complications. Ependymoma / therapy. Parietal Lobe / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Wechsler Scales

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 John Wiley & Sons, Ltd.
  • (PMID = 10871722.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Hong TS, Mehta MP, Boyett JM, Donahue B, Rorke LB, Zeltzer PM: Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study. Pediatr Blood Cancer; 2005 Oct 15;45(5):676-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of treatment failure in infants with primitive neuroectodermal tumors who were treated on CCG-921: a phase III combined modality study.
  • PURPOSE: To analyze patterns of treatment failure in infants with primitive neuroectodermal tumors (PNETs) who were treated primarily with chemotherapy in a large multi-institutional study.
  • MATERIALS AND METHODS: Sixty-five prospectively staged patients with PNET confirmed by central pathology review, who were 18 months or younger were treated on Children's Cancer Group Study 921 (CCG-921) primarily with chemotherapy.
  • Forty-six patients had posterior fossa (PF) primary tumors and 19 patients had supratentorial (ST) primaries.
  • Patterns of sites of initial treatment failure were analyzed and compared to failure patterns of 180 older children who had PF-PNETs, and 44 older children with ST-PNETs who were treated on the same protocol.
  • Cumulative 5-year relapse incidence (+/-SE) for younger patients with PF-PNETs was 64.5 +/- 8.9% for patients without metastases (M0) compared to 71.4 +/- 13.4% for patients with metastases (M+).
  • The overall treatment failure rate was significantly higher for younger compared to older patients with PF-PNET and ST-PNET.
  • There was no statistically significant difference in relapse patterns between patients with PF primary tumors and ST primaries when stratified by stage.
  • All patients had a high risk of recurrence at primary tumor site.
  • Younger patients who had PF primary tumors without metastasis at presentation were significantly more likely to relapse in PF than older patients.
  • CONCLUSIONS: Despite aggressive chemotherapy, younger children with PNETs have high rates of treatment failure and fare worse than high-risk, older patients with PF-PNETs, indicating the need to maximize local, regional, and systemic therapies.
  • [MeSH-major] Brain Neoplasms / therapy. Neuroectodermal Tumors, Primitive / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Infant. Infratentorial Neoplasms / mortality. Infratentorial Neoplasms / pathology. Infratentorial Neoplasms / therapy. Neoplasm Recurrence, Local. Supratentorial Neoplasms / mortality. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / therapy. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007595.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


13. Mangiola A, Maira G, De Bonis P, Porso M, Pettorini B, Sabatino G, Anile C: Glioblastoma multiforme in the elderly: a therapeutic challenge. J Neurooncol; 2006 Jan;76(2):159-63
Genetic Alliance. consumer health - Glioblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme in the elderly: a therapeutic challenge.
  • INTRODUCTION: Elderly patients with glioblastoma multiforme (GBM) are frequently excluded from cancer therapy trials, treated suboptimally or not treated at all.
  • The goal of the present study was to evaluate the efficacy of different treatment options in terms of survival in an elderly population affected with GBM.
  • MATERIALS AND METHODS: About 34 Patients with primary supratentorial GBM aged 65 or higher were included in this study.
  • After surgery they received radiation therapy, chemotherapy and radioimmunotherapy in different combinations.
  • Survival according to adjuvant therapy has been 21 months (radiotherapy, chemotherapy, radioimmunotheraphy), 18 months (radiotherapy, chemotherapy) and 7 months (radiotherapy) (P=0.0001).
  • [MeSH-major] Glioblastoma / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures. Prognosis. Radioimmunotherapy. Survival. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1991 Aug;36(2):106-11 [1891754.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):261-7 [12356356.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):443-7 [10717518.001]
  • [Cites] Oncology (Williston Park). 1995 Mar;9(3):229-34; discussion 237-8, 243 [7669516.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):187-93 [10533732.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):113-25 [12784877.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):657-62 [12548608.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):62-6; discussion 66-7 [8121570.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):58-62 [14765388.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):41-5 [2170591.001]
  • [Cites] Neurology. 1996 Oct;47(4):901-5 [8857716.001]
  • [Cites] J Neurooncol. 1992 Feb;12(2):125-30 [1560257.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1634-42 [8635069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):981-7 [9869219.001]
  • [Cites] Neurology. 1995 May;45(5):929-33 [7746409.001]
  • [Cites] Neurosurgery. 2001 Dec;49(6):1288-97; discussion 1297-8 [11846927.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):45-60; discussion 60-1 [8121569.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):63-7 [14765389.001]
  • [Cites] Lancet. 1982 Apr 17;1(8277):885-7 [6122104.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):2067-75 [1941065.001]
  • [Cites] Cancer. 2004 May 15;100(10 ):2208-14 [15139066.001]
  • [Cites] J Neurooncol. 1997 Jul;33(3):201-4 [9195491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):835-9 [8040031.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1175-81 [12816260.001]
  • [Cites] Surg Neurol. 2004 Sep;62(3):207-13; discussion 214-5 [15336860.001]
  • [Cites] Radiother Oncol. 1994 Nov;33(2):113-6 [7535939.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Sep;48(3):220-8 [15499296.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):635-44 [15497116.001]
  • [Cites] J Neurooncol. 1999 May;42(3):215-26 [10433105.001]
  • [Cites] Oncology. 1998 Jan-Feb;55(1):1-6 [9428367.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 16132492.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M, North American Brain Tumor Consortium: Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol; 2003 Jun 15;21(12):2305-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
  • This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG.
  • PATIENTS AND METHODS: Adults with recurrent supratentorial MG for whom surgery, radiation, and/or chemotherapy failed were eligible.
  • Treatment included oral TMZ 150 or 200 mg/m2/d, days 1 through 5, and cRA 100 mg/m2/d, days 1 to 21, every 28 days.
  • Primary end point was progression-free survival at 6 months (PFS 6); secondary end points included response, survival, and PFS12.
  • RESULTS: Eighty-eight eligible patients (glioblastoma multiforme [n = 40]; anaplastic gliomas [n = 48; astrocytoma, 28; oligodendroglioma, 14; mixed glioma, six]) received treatment.
  • Among 499 treatment cycles, the most common grade 3/4 events included granulocytopenia (1.8%), thrombocytopenia (1.4%), and hypertriglyceridemia (1.2%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Glioma / drug therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Disease Progression. Female. Humans. Isotretinoin / administration & dosage. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12805331.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR03186; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCRR NIH HHS / RR / MO1-RR00056; United States / NCI NIH HHS / CA / UO1CA62399; United States / NCI NIH HHS / CA / UO1CA62405; United States / NCI NIH HHS / CA / UO1CA62407-08; United States / NCI NIH HHS / CA / UO1CA62421
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EH28UP18IF / Isotretinoin
  •  go-up   go-down


15. Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C: [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Orv Hetil; 2009 Oct 18;150(42):1937-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic management of central nervous system lymphomas in a single hematological institute].
  • Primary central nervous system lymphoma is defined as an extranodal lymphoma arising in the central nervous system in the absence of systemic disease.
  • Because of their rare occurrence among lymphomas, optimal treatment could hardly be established.
  • AIMS: In this retrospective survey we analyzed the result of combined treatment (systemic and intrathecal chemotherapy followed by consolidation radiotherapy) in patients with primary or relapsed central nervous system lymphomas diagnosed and treated in our hematological department between 1998-2009.
  • PATIENTS AND METHODS: During this period (mean follow-up of 13.2 months) from 427 patients with newly diagnosed non-Hodgkin's lymphomas, 22 primary central nervous system lymphoma was diagnosed (5.15%, 16 cerebral and 6 spinal cord lymphoma cases).
  • Epidural lymphomas were treated with local radiotherapy (30-40 Gy), except for patients with follicular lymphomas getting rituximab-containing polychemotherapy (R + CHOP regimen) before irradiation.
  • In cerebral lymphoma (every patients had supratentorial localization) the following combined therapy protocol was used: up to three courses of high dose methotrexate (HD MTX 3g/m 2 in a single dose for 4 hours lasting drop-infusion) were given at 4-week intervals, followed by leucovorin-rescue 24 hours after MTX infusion.
  • Intrathecal combination of methotrexate, cytosin-arabinosid and dexamethasone was given three times after HD MTX infusion.
  • In complete response after chemotherapy (evaluated by cranial MRI or CT, PET/CT), whole-brain irradiation was used in a total dose of 30 Gy.
  • RESULTS: Complete remission has been achieved in 9 patients with cerebral and in 4 patients with spinal cord lymphoma (13/22; 59.0%), however, one relapsed patient became resistant and later expired, despite salvage therapy.
  • Mean of the overall survival (OS) in cerebral lymphoma was 19.5 (3-46, median of 10) months, in epidural group 14.1 (2-76, median of 5) months, whilst mean time to progression (TTP) was 4.5 (2-6.5, median of 4 months).
  • Acute toxicity of chemotherapy was usually hematological, moreover, in 8 patients impaired renal function and sepsis developed.
  • CONCLUSION: In primary central nervous system lymphoma, basic treatment HD methotrexate together with intrathecal combination of methotrexate + cytosin-arabinosid + dexamethasone followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study.
  • In case of relapse or progression, other salvage regimens containing HD Ara-C alternating with HD MTX could reduce the treatment failure, as well.
  • After therapy PET/CT was negative in five patients with prolonged disease-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Cranial Irradiation. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Epidural Space. Female. Humans. Hungary / epidemiology. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Positron-Emission Tomography. Prednisone / administration & dosage. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Rituximab. Salvage Therapy / methods. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812012.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  •  go-up   go-down


16. Saran F, Baumert BG, Creak AL, Warrington AP, Ashley S, Traish D, Brada M: Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET. Pediatr Blood Cancer; 2008 Mar;50(3):554-60
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Between 1991 and 2005, 12 patients with locally recurrent medulloblastoma and two patients with residual supratentorial PNET were treated with hypofractionated stereotactic conformal radiotherapy (SCRT).
  • Nine of 12 patients underwent resection at recurrence and 13 patients received at least one cycle of chemotherapy prior to SCRT.
  • All received focal SCRT (30-40 Gy/6-8 #) using non-coplanar arcs (n = 6) or fixed conformal non-coplanar fields (n = 8).
  • However, overall long-term disease control is rare and limited by the occurrence of CSF mediated relapses, which thus could benefit from intensive systemic chemotherapy as part of the primary relapse strategy even in local recurrences.
  • Larger multi-national studies will be necessary to assess the value of such combined treatment approaches.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Dose Fractionation. Medulloblastoma / radiotherapy. Neuroectodermal Tumors, Primitive / radiotherapy. Radiotherapy, Conformal / methods. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Recurrence, Local / radiotherapy. Neoplasm, Residual. Palliative Care. Retrospective Studies. Stereotaxic Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17941071.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Gutenberg A, Schulten HJ, Gunawan B, Ludwig HC, Brück W, Larsen J, Rohde V: CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy. Pediatr Neurosurg; 2009;45(1):61-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the very unusual case of a young woman suffering from a brain tumor 22 years after a stage IV spinal neuroblastoma as an infant, demonstrating the difficulties of differentiating late neuroblastoma relapse from secondary supratentorial primitive neuroectodermal tumor (sPNET).
  • Lacking specific immunohistochemical features, the first cerebral tumor at the age of 21 was regarded as sPNET, and we pursued a therapeutic approach consisting of neurosurgical resection as well as irradiation and high-dose alkylator-based chemotherapy according to the HIT2000 protocol.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Neuroblastoma / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genetic Markers. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258732.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


18. Smee RI, Williams JR: Medulloblastomas-primitive neuroectodermal tumours in the adult population. J Med Imaging Radiat Oncol; 2008 Feb;52(1):72-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients completed craniospinal radiotherapy (35-36 Gy at 1.8-2.0 Gy fractions) barring one patient, who died of surgical complications during his radiotherapy.
  • Chemotherapy was given in five of the nine patients postradiotherapy.
  • There were two posterior fossa recurrences, with associated supratentorial and extra central nervous system disease.
  • Of the 10 primary patients 7 are alive with no evidence of disease, 2 died because of disease, with 1 intercurrent death.
  • One patient developed a second malignancy.
  • [MeSH-major] Cerebellar Neoplasms / epidemiology. Medulloblastoma / epidemiology. Neuroectodermal Tumors, Primitive / epidemiology
  • [MeSH-minor] Adolescent. Adult. Databases, Factual / statistics & numerical data. Female. Follow-Up Studies. Humans. Intracranial Pressure. Male. Neoplasm Recurrence, Local. Neurosurgical Procedures. New South Wales / epidemiology. Radiotherapy, Adjuvant. Rare Diseases. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373831.001).
  • [ISSN] 1754-9477
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 29
  •  go-up   go-down


19. Krishnamurthy S, Powers SK, Witmer P, Brown T: Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors. Lasers Surg Med; 2000;27(3):224-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal light dose for interstitial photodynamic therapy in treatment for malignant brain tumors.
  • BACKGROUND AND OBJECTIVE: The primary goal was to determine the maximal tolerable light dose that can be administered to patients undergoing multifiber interstitial photodynamic therapy (PDT) of malignant brain tumors at a fixed dose of photosensitizer.
  • CONCLUSIONS: Increasing the total light dose delivered to the tumor increases the odds of having a permanent neurologic deficit but does not increase survival or time to tumor progression.
  • [MeSH-major] Glioma / drug therapy. Hematoporphyrin Photoradiation / methods. Laser Therapy. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dihematoporphyrin Ether / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Radiation. Humans. Middle Aged. Neoplasm Recurrence, Local. Photochemotherapy. Photosensitizing Agents. Stereotaxic Techniques. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11013384.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


20. Abel TJ, Chowdhary A, Thapa M, Rutledge JC, Geyer JR, Ojemann J, Avellino AM: Spinal cord pilocytic astrocytoma with leptomeningeal dissemination to the brain. Case report and review of the literature. J Neurosurg; 2006 Dec;105(6 Suppl):508-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient then underwent chemotherapy, and total spine magnetic resonance (MR) imaging 2 months later demonstrated stability in the size of the spinal cord tumor and a decrease in the associated syrinx.
  • However, an MR image of the head demonstrated two new areas of supratentorial subarachnoid leptomeningeal spread of the primary spinal cord tumor at the 2-month follow-up examination.
  • This case illustrates a unique instance of supratentorial leptomeningeal dissemination of an intramedullary spinal cord PCA in a child.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery






Advertisement